Recent Updates
Recently added Catalysts

Combined diphtheria, tetanus, acellular pertussis vaccine

Phase 3

Diphtheria | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Sep 9, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment4,116

FDA Designations

No designations recorded

Clinical trial landscape

Combined diphtheria, tetanus, acellular pertussis vaccine · 1 trial · 3 indications

Phase 3 1
NCT00109330A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td VaccineDiphtheria
COMPLETED4,116 Analytics
PHASE3COMPLETED
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
Diphtheria
NCT001093304,116
Unlock trial analytics

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposePREVENTION

Interventions

NameTypeDescription
Combined diphtheria, tetanus, acellular pertussis vaccineBIOLOGICAL -
Unlock Study Design Details

Eligibility Criteria

Age Range10 Years to 18 Years
SexALL
Healthy VolunteersYes
Study Sites44

Inclusion Criteria: * Healthy adolescents with history of completed routine vaccination against diphtheria, tetanus, and pertussis (DTP). Exclusion Criteria: * Use of any other investigational drug or vaccine 30 days preceding study vaccination. * Chronic administration of immunosuppressants. * A...

Countries:United States
Unlock Eligibility Criteria